Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. (MDRX) is a healthcare technology company that focuses on healthcare data and technology solutions for providers, payers, and biopharma organizations. News about Veradigm often centers on how the company uses its platforms, data, connectivity, and expertise within the Veradigm Network to support clinical, operational, and financial performance in healthcare.
Investors and industry observers following MDRX news can expect updates on business performance, financing, and capital structure, as reflected in Veradigm’s announcements about financial outlooks, cash and debt levels, and debt financing arrangements. The company also issues news about its progress on financial reporting, including the filing of its Annual Report on Form 10-K with restated financial statements and its efforts to become current in SEC filings and pursue relisting on a national stock exchange.
Operational and client-focused news includes case studies and collaborations that highlight Veradigm’s role in value-based care, payer–provider integration, and revenue cycle management. Examples include recognition through a KLAS Points of Light Award for delivering insights at the point of care and announcements about organizations selecting Veradigm Revenue Cycle Services, Coding Services, and related offerings such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath.
Veradigm also issues news on product and capability developments, such as applying artificial intelligence to deidentified EHR data to generate real-world evidence for GLP-1 therapies, and on thought leadership initiatives like the Smart Medicine Podcast. Governance and corporate updates, including leadership appointments and amendments to the company’s stockholder rights plan, are additional recurring themes. For a comprehensive view of MDRX-related developments, this news page aggregates these announcements and related coverage in one place.
Veradigm (OTCMKTS: MDRX), a healthcare data and technology solutions provider, has announced the extension of its Stockholder Rights Plan for an additional six months. The Board of Directors has amended the plan, originally adopted on February 26, 2024, to now expire on February 20, 2026.
Key changes include modifying the triggering threshold to 20% ownership of outstanding shares, applicable to both direct and synthetic ownership through derivative positions. The extension aims to protect stockholder value while the company works towards becoming current in financial reporting and relisting on a national stock exchange, expected in 2026.
Veradigm (OTCMKTS: MDRX) has appointed Don Trigg as its new Chief Executive Officer and Board member, effective September 2, 2025. Trigg brings over two decades of healthcare technology experience, most recently serving as CEO of apree health, which was acquired by Elevance Health in 2024.
Prior to apree, Trigg held significant positions at Cerner Corporation, including serving as President where he managed the company's $5 billion revenue operations. At Cerner, he oversaw the EMR business, revenue cycle, and Strategic Growth initiatives, while successfully modernizing technical platforms and expanding into new markets.
Under Trigg's leadership at apree health, the company achieved strong patient satisfaction and top-quartile performance in healthcare effectiveness measures while reducing care costs.
Veradigm (OTCMKTS: MDRX) has provided a comprehensive financial update for Q1 2025 and outlook for the fiscal year. The company reported Q1 2025 revenue between $145-147 million and secured deals worth $30 million in annual contract value, representing a 25% increase year-over-year.
Key financial positions include cash and equivalents of $272 million as of March 31, 2025, and debt of $208 million. Veradigm recently completed a new debt financing of up to $100 million, with $75 million drawn at closing. The company expects to become current with SEC filings in 2026 and subsequently seek relisting of its common stock.
For fiscal year 2025, Veradigm projects revenue to remain approximately flat compared to 2024 ($583-588 million) while maintaining positive net cash position.
Veradigm (OTCMKTS: MDRX) has received a 2025 KLAS Points of Light Award for its successful collaboration with Metroplex Medical Centres and a major healthcare payer organization. The case study demonstrated how integrating real-time alerts into Metroplex's EHR system significantly improved healthcare delivery efficiency. The implementation resulted in a 20-hour per week time savings in searching for data and reduced unnecessary emergency department visits.
The solution addressed the challenge of fragmented data access across seven different systems by integrating four types of real-time risk and quality alerts into Metroplex's EHRs. This integration helped improve clinical decision support, reduce healthcare provider burnout, advance patient care, and lower overall healthcare costs. The project showcases Veradigm's commitment to advancing value-based care through improved collaboration between payers and providers.
Veradigm (OTCMKTS: MDRX) has announced a significant advancement in using artificial intelligence (AI) to analyze real-world evidence (RWE) for GLP-1 receptor agonists, including semaglutide and tirzepatide. The company's AI technology can now extract valuable insights from electronic health records (EHR) data that previously required manual review.
The new AI-driven curation system offers key capabilities including: tracking therapy discontinuation reasons, monitoring side effects, identifying off-brand use, tracking outcomes, and analyzing social determinants of health. This technology leverages Veradigm Network's national EHR database to provide life science organizations with deeper insights into patient experiences and outcomes.
The company will present research findings on GLP-1 persistence and therapy discontinuation reasons at ISPOR 2025 on May 14.
Veradigm (OTCMKTS: MDRX) has been ranked as the #1 overall provider of payer analytics solutions for health plans by Black Book Research for the second consecutive year. The company's Payer Analytics platform secured top rankings in 9 out of 18 performance categories, including Data Integration Efficiency, Data Standardization Quality, and Scalability.
The independent assessment, based on feedback from over 1,300 users across 400+ payer organizations, highlighted Veradigm's excellence in User Interface Intuitiveness, Customer Support Responsiveness, and System Reliability. The platform is a important component of Veradigm's Comprehensive Outcomes and Realization (CORE) solution strategy, designed to help health plans improve outcomes and control costs while providing a 360-degree view of healthcare data.
Veradigm (OTCMKTS: MDRX) announced that Syracuse Orthopedic Specialists has selected its Revenue Cycle Services and Coding Services solutions to enhance their financial operations. The orthopedic care provider, already utilizing Veradigm Revenue Analytics, Practice Management, and Payerpath, aims to optimize revenue cycle management and improve operational efficiency.
The EHR-agnostic healthcare RCM service is designed to reduce accounts receivable days, minimize claim errors, and decrease denials. The Coding Services solution integrates with existing EHR systems to identify deficiencies and optimize coding workflow, focusing on increasing first-pass claims and accelerating revenue generation.
Syracuse Orthopedic Specialists' CEO Mike Humphrey emphasized the decision to extend their partnership with Veradigm, citing the company's expertise in handling billing and reducing staff burden while increasing revenue.
Veradigm (MDRX) has provided financial updates for fiscal 2023, 2024, and an outlook for 2025. For fiscal 2023, the company estimates:
- Revenue: $620-625 million (including $19M in favorable customer settlements)
- GAAP Net Income: $62-65 million
- Adjusted EBITDA: $139-144 million
- Net Cash: $239 million
For fiscal 2024, preliminary estimates show:
- Revenue: $583-588 million
- GAAP Net Loss: $46-49 million
- Adjusted EBITDA: $85-90 million
- Net Cash: $87 million
The company expects 2025 revenue to remain approximately flat compared to 2024, with positive net cash position. Interim CEO Tom Langan expressed confidence in the business model and mentioned focus on remediating material weaknesses and relisting their common stock.
FAQ
What is the current stock price of Veradigm (MDRX)?
What is the market cap of Veradigm (MDRX)?
